News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to Accelerate Learning on Its Majority Investment by Providence Equity PartnersFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Financial Advisor for Steward Health Care’s Sale of Utah Health Care SitesFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to OPEN Health on the Acquisition of Acsel HealthFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Sole Placement Agent for Spruce Biosciences’ (Nasdaq: SPRB) $53.6 Million Private PlacementFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for CureVac’s (Nasdaq: CVAC) Upsized $250 Million Follow-On OfferingFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Roivant Sciences’ (Nasdaq:ROIV) $200 Million Follow-On OfferingFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Avalo Therapeutics’ (Nasdaq: AVTX) $15 Million Follow-On OfferingFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Olink’s (Nasdaq: OLK) $117 Million Follow-On OfferingJanuary 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Fulcrum Therapeutics’ (Nasdaq: FULC) $125 Million Follow-On OfferingJanuary 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to AMF Medical SA on its Sale to Tandem Diabetes Care, Inc. (Nasdaq: TNDM)December 2022
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Replimune’s (Nasdaq: REPL) $225 Million Follow-On OfferingDecember 2022
